

Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease

May 21 2019, 8:00 AM EDT

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)

May 14 2019, 8:00 AM EDT

Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights

May 10 2019, 4:15 PM EDT

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	322.01m
Last Price	\$6.55
52-Week	\$6.259 - \$18.90

05/24/2019 04:00 PM EDT

Investor Relations

Sofia Warner
Director, Investor Relations
T: +1 (646) 813-4710
swarner@abeonatherapeutics.com

Management Team

João Siffert, MD

Chief Executive Officer, Head of Research & Development and Chief Medical Officer

Timothy J. Miller, PhD

President & Chief Scientific Officer

Christine Silverstein

Chief Financial Officer

Max Colao

Chief Commercial Officer

Edward Carr

Chief Accounting Officer

Juan Ruiz, MD, PhD

Head of European Medical Affairs

Neena Patil

Senior Vice President, General Counsel and Corporate Secretary

Jay Bircher

Senior Vice President, Quality & Technical Operations

Kristina Maximenko

Vice President, Human Resources

Scott Nogi

Vice President, Business Operations

Abeona Therapeutics, Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.